Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sofosbuvir + ledipasvir
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose combination of sofosbuvir and ledipasvir, two direct-acting antivirals (DAAs) used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir is a nucleotide analog that acts as an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, while ledipasvir is an inhibitor of the HCV NS5A protein. This combination is particularly significant in Egypt for treating genotype 4 HCV, the most prevalent strain in the region. The National Liver Institute in Egypt has conducted specific clinical trials evaluating a half-dose generic formulation (Heterosofir) for safety and efficacy in pediatric populations aged 3 to 12 years, demonstrating high sustained virological response (SVR) rates.
- Brand names
- HeterosofirHarvoni
- Other names
- Sofosbuvir/LedipasvirLedipasvir/Sofosbuvir
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on sofosbuvir + ledipasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sofosbuvir + ledipasvir.